Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.46 USD
Change Today +0.0009 / 0.20%
Volume 65.0K
CRDC On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 8:10 PM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).

cardica inc (CRDC) Snapshot

Open
$0.44
Previous Close
$0.46
Day High
$0.48
Day Low
$0.44
52 Week High
09/22/14 - $1.32
52 Week Low
05/7/15 - $0.36
Market Cap
40.6M
Average Volume 10 Days
49.3K
EPS TTM
$-0.25
Shares Outstanding
89.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CARDICA INC (CRDC)

Related News

No related news articles were found.

cardica inc (CRDC) Related Businessweek News

No Related Businessweek News Found

cardica inc (CRDC) Details

Cardica, Inc. designs, manufactures, and markets automated anastomotic systems for use by cardiac surgeons to perform coronary bypass surgery in the United States and internationally. It provides C-Port Distal Anastomosis systems, including C-Port xA Anastomosis systems to perform an end-to-side distal anastomosis by attaching the end of a bypass graft to a coronary artery downstream of an occlusion or narrowing; C-Port Flex A Anastomosis systems to enable automated anastomoses to be performed as part of coronary artery bypass grafting procedures; and PAS-Port Proximal Anastomosis systems to perform an end-to-side proximal anastomosis between a saphenous vein and the aorta. It also offers endoscopic microcutter products comprising MicroCutter XCHANGE 30, MicroCutter FLEXCHANGE 30, and MicroCutter XCHANGE 45 cartridge based microcutter devices to facilitate endoscopic procedures requiring cutting and stapling; and MicroCutter XPRESS 30 and MicroCutter XPRESS 45 multi-fire endolinear microcutter devices for the bariatric and thoracic surgery markets. In addition, the company licenses its intellectual property in the robotics field in diagnostic or therapeutic medical procedures. The company markets its Port Distal Anastomosis systems through its direct sales force, as well as through independent manufacturers’ representatives and distributors. The company was formerly known as Vascular Innovations, Inc. and changed its name to Cardica, Inc. in November 2001. Cardica, Inc. was founded in 1997 and is headquartered in Redwood City, California.

48 Employees
Last Reported Date: 05/12/15
Founded in 1997

cardica inc (CRDC) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $455.8K
Vice President of Sales and Marketing
Total Annual Compensation: $114.6K
Compensation as of Fiscal Year 2014.

cardica inc (CRDC) Key Developments

Cardica Announces Transfer Of Listing To Nasdaq Capital Market

On June 17, 2015, Cardica, Inc. received a letter from the staff (the “Staff”) of The NASDAQ Stock Market LLC (“Nasdaq”) stating that the Staff has approved Cardica’s application to list its common stock on the Nasdaq Capital Market. In addition, the Staff’s letter confirmed that although Cardica has not been able to regain compliance with Nasdaq Listing Rule 5450(a)(1), which requires that Cardica’s common stock have a closing bid price of at least $1.00 per share, Cardica has an additional 180 day period, or until December 7, 2015, to regain compliance with this bid price requirement. The Staff’s letter further states that if, at any time during this additional time period, the closing bid price of Cardica’s common stock is at least $1.00 for a minimum of 10 consecutive business days, the Staff will provide written confirmation of compliance and the matter will be closed. The Staff’s letter also states that if Cardica is not able to regain compliance with the minimum bid price requirement by December 7, 2015, the Staff will provide written notification that Cardica’s common stock will be delisted from the Nasdaq Capital Market. If this occurs, Cardica would be able to appeal the Staff’s determination to the Hearings Panel, which would stay the delisting of Cardica’s common stock until the Hearings Panel makes a determination with respect to the appeal.

Cardica, Inc. Fails To Regain Compliance With Nasdaq Listing Rule 5450(a)(1)

On June 9, 2015, Cardica, Inc. received from the staff of The NASDAQ Stock Market LLC (“Nasdaq”) a letter stating that Cardica had failed to regain compliance with Nasdaq Listing Rule 5450(a)(1) during the 180 day period following Cardica’s receipt of the Staff’s letter of December 9, 2014. In the December 9, 2014, letter, the Staff advised Cardica that the bid price of Cardica’s common stock had closed at less than $1 per share over the previous 30 consecutive business days and that Cardica had 180 calendar days, or until June 8, 2015, to regain compliance with Nasdaq Listing Rule 5450(a)(1). To regain compliance, the closing bid price of Cardica’s common stock needed to have been at least $1 per share for a minimum of 10 consecutive business days before June 8, 2015. The Delisting Notice further states that unless Cardica applies to transfer its common stock to The Nasdaq Capital Market or requests an appeal of this determination to the Nasdaq Listing Qualifications Panel on or before June 16, 2015, the Staff has determined that the Cardica common stock will be scheduled for delisting at the opening of business on June 18, 2015. Cardica has determined to apply to transfer its common stock to The Nasdaq Capital Market, which according to the letter will stay the delisting of the Cardica common stock for an additional 180 days during which Cardica will have the opportunity to cure the bid price deficiency.

Cardica Inc. Announces Unaudited Earnings Results for Third Quarter and Nine Months Ended March 31, 2015

Cardica Inc. announced unaudited earnings results for third quarter and nine months ended March 31, 2015. For the quarter, the company reported revenue of $564,000, loss from operations of $4,724,000, net loss of $4,824,000 or $0.05 basic and diluted per share compared to the revenue of $934,000, loss from operations of $4,254,000, net loss of $4,379,000 or $0.09 basic and diluted per share for the same quarter a year ago. For the year to date, the company reported revenue of $2,289,000, loss from operations of $15,023,000, net loss of $15,331,000 or $0.17 basic and diluted per share compared to the revenue of $2,590,000, loss from operations of $11,953,000, net loss of $12,290,000 or $0.24 basic and diluted per share for the same period a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CRDC:US $0.46 USD +0.0009

CRDC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Olympus Corp ¥4,715 JPY +15.00
View Industry Companies
 

Industry Analysis

CRDC

Industry Average

Valuation CRDC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.2x
Price/Book 4.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CARDICA INC, please visit www.cardica.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.